UBS Group
LTRN icon

UBS Group’s Lantern Pharma LTRN Stock Holding History

UBS Group’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.4K Buy
16,632
+6,555
+65% +$19.2K ﹤0.01% 7388
2026
Q1 		$13.8K Sell
10,077
-550
-5% -$1.54K ﹤0.01% 8203
2025
Q4 		$32.2K Sell
10,627
-22,529
-68% -$83.9K ﹤0.01% 7484
2025
Q3 		$144K Buy
33,156
+8,503
+34% +$35.5K ﹤0.01% 6875
2025
Q2 		$77.9K Sell
24,653
-3,438
-12% -$11.6K ﹤0.01% 7434
2025
Q1 		$99.4K Buy
28,091
+407
+1% +$1.69K ﹤0.01% 7054
2024
Q4 		$88.3K Buy
27,684
+813
+3% +$2.78K ﹤0.01% 6954
2024
Q3 		$98.6K Buy
26,871
+1,371
+5% +$5.65K ﹤0.01% 6382
2024
Q2 		$119K Hold
25,500
– – ﹤0.01% 6058
2024
Q1 		$224K Sell
25,500
-458
-2% -$2.45K ﹤0.01% 5777
2023
Q4 		$111K Sell
25,958
-1,042
-4% -$3.67K ﹤0.01% 6115
2023
Q3 		$92.1K Hold
27,000
– – ﹤0.01% 5885
2023
Q2 		$152K Hold
27,000
– – ﹤0.01% 5672
2023
Q1 		$130K Buy
27,000
+12,159
+82% +$63.9K ﹤0.01% 5711
2022
Q4 		$89.6K Buy
14,841
+2,841
+24% +$14.2K ﹤0.01% 6206
2022
Q3 		$57K Sell
12,000
-50
-0.4% -$269 ﹤0.01% 6218
2022
Q2 		$69K Sell
12,050
-1,886
-14% -$11.2K ﹤0.01% 5690
2022
Q1 		$100K Buy
13,936
+826
+6% +$5.52K ﹤0.01% 5916
2021
Q4 		$105K Buy
13,110
+5,433
+71% +$49.6K ﹤0.01% 6275
2021
Q3 		$86K Sell
7,677
-567
-7% -$7.34K ﹤0.01% 5932
2021
Q2 		$121K Buy
8,244
+6,078
+281% +$93.9K ﹤0.01% 5737
2021
Q1 		$39K Buy
+2,166
New +$38K ﹤0.01% 6785
2020
Q4 		– Sell
-112
Closed -$2K – 8589
2020
Q3 		$2K Sell
112
-1,421
-93% -$20.6K ﹤0.01% 7668
2020
Q2 		$19K Buy
+1,533
New +$19.8K ﹤0.01% 6588

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

UBS Group's LTRN Position: Q2 2026 in Review

UBS Group increased its Lantern Pharma (LTRN) stake by 65% in Q2 2026, buying an estimated $19.2K and bringing the position to 16,632 shares worth $69.4K. The position accounts for ﹤0.01% of the portfolio, ranked #7388.

UBS Group first reported a position in LTRN in Q2 2020 and has held it in 24 quarters since. The position peaked at $224K in Q1 2024. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • UBS Group held 16,632 shares of Lantern Pharma worth $69.4K as of Q2 2026.
  • UBS Group bought 6,555 Lantern Pharma shares in Q2 2026, an estimated $19.2K.
  • Lantern Pharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7388 holding.
  • UBS Group first reported a position in Lantern Pharma in Q2 2020 and has held it in 24 quarters since.
  • UBS Group's Lantern Pharma position peaked at $224K in Q1 2024.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.